NRIX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Nurix Therapeutics Inc (NRIX) is not a strong buy at this moment for a beginner investor with a long-term focus. While the technical indicators show some bullish momentum and analysts maintain positive ratings, the lack of recent significant news, weak financial performance, and absence of proprietary trading signals suggest a cautious approach. The stock may be worth monitoring for future catalysts in 2026 and beyond, but it does not present a compelling entry point right now.
The technical indicators show a bullish trend with MACD above 0 and positively contracting, RSI in the neutral zone at 64.101, and moving averages in a bullish alignment (SMA_5 > SMA_20 > SMA_200). The stock is trading near its resistance level (R1: 16.946) in pre-market, suggesting limited immediate upside.
Analysts maintain positive ratings with price targets significantly above the current price (ranging from $28 to $35). Upcoming clinical trial updates and potential catalysts in 2026 and 2027 could drive future growth.
The company's financial performance is weak, with revenue dropping by -66.12% YoY in Q1 2026 and a net loss of -$87.17 million. There are no significant hedge fund or insider trading trends, and no recent news or congress trading data to act as a catalyst.
In Q1 2026, revenue dropped significantly by -66.12% YoY to $6.25 million. However, net income improved YoY by 54.70% to -$87.17 million, and EPS increased by 17.91% to -0.79. Gross margin remains at 100%, but the overall financials indicate weak growth trends.
Analysts maintain positive ratings with multiple firms assigning Buy or Overweight ratings. Price targets range from $28 to $35, indicating significant upside potential from the current price. Analysts highlight upcoming clinical trial updates and potential catalysts in 2026 and 2027 as key growth drivers.
